Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 7.63%
As of Thursday, July 16, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 7.63%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.23%
As of Tuesday, July 07, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.31%
As of Wednesday, June 17, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.31%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.69%
As of Thursday, June 04, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.69%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 7.84%
As of Tuesday, June 02, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 7.84%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,856.8 | $569.9 | 53% |
|
| Shares Out (Mil) | 224.1 | 44.8 | 79% |
|
| Institutional Ownership | 98.5% | 84.6% | 80% |
|
| Float (Mil) | 184.4 | 45.1 | 72% |
|
| Beta | 0.88 | 0.67 | 52% |
|
| Avg Daily Volume (000s) | 1,919 | 294 | 81% |
|
| Price Change (52-week) |
(27.8%) | 65.2% | 26% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 6.7% | 86% |
|
| Net Income (5yr) | (11.3%) | (2.0%) | 28% |
|
| EPS (5yr) | 11.1% | 14.9% | 48 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($0.390) | ($1.582) | ($1.478) | |
| Month Ago EPS | ($0.390) | ($1.553) | ($1.538) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.338) | ($1.398) | ($1.256) | |
| Year/Year Chg | (2.5%) | 11.4% | (15.7%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $52 | $230 | 20% |
|
| Net Income (TTM) (Mil) | ($291) | ($11) | 5% |
|
| EPS (TTM) | ($1.446) | ($0.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($226) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $317 | $4 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $7 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,576 | $493 | 46% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.19 | 2.89 | 67% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (336.4%) | 65.9% | 1% |
|
| Net Margin | (558.2%) | (0.2%) | 1% |
|
| ROA | (51.0%) | (25.5%) | 11% |
|
| ROE | (68.6%) | (21.4%) | 12% |
|
| Liabilities to Assets | 20.6% | 35.5% | 13% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 7/30/2026.
